According to IMARC Group, the global Oncology Based In-Vivo CRO Market Size reached USD 1.4 Billion in 2025 and is projected to reach USD 2.5 Billion by 2034, expanding at a CAGR of 6.29% during 2026-2034. This steady growth reflects the rising global burden of cancer, expanding demand for personalized oncology treatments, ongoing technological advancements in tumor modeling, and increasing regulatory emphasis on robust preclinical validation.

Oncology Based In-Vivo CRO Industry Overview

Oncology based in-vivo CROs provide preclinical research services centered on animal tumor models, enabling researchers to study cancer biology, evaluate therapeutic candidates, and generate pharmacokinetic and pharmacodynamic data ahead of clinical trials. These organizations support pharmaceutical companies, biotechnology firms, and academic research institutions across the drug development continuum.

Oncology based in-vivo CRO services span a broad range of use cases:

• Tumor model development: Syngeneic, xenograft, and patient-derived xenograft (PDX) models replicating human tumor biology
• Efficacy and pharmacology studies: Evaluating chemotherapy, targeted therapy, immunotherapy, and combination treatment regimens
• Personalized medicine research: Supporting biomarker identification and patient stratification for tailored cancer treatments
• Regulatory-focused preclinical studies: Generating data packages that meet global regulatory compliance requirements
• Hospital and rehabilitation center collaborations: Supporting translational research and post-treatment outcome studies

Global Oncology Based In-Vivo CRO Market Size & Key Statistics

Below are the key Oncology Based In-Vivo CRO Market statistics drawn from IMARC Group's comprehensive market analysis:

Request for a Sample Report for Detailed Oncology Based In-Vivo CRO Market Share Evaluation: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample

Key Market Drivers & Oncology Based In-Vivo CRO Market Trends in 2025

Several powerful forces are shaping Oncology Based In-Vivo CRO Market Trends and fuelling sustained growth expectations across global preclinical oncology research markets:

1. Rising Prevalence of Cancer Worldwide

The rising prevalence of cancer is a significant driver behind the growth of the oncology based in-vivo CRO market. Cancer continues to be a major public health challenge worldwide, with increasing incidence rates across various types of cancers. For instance, the IARC's 2022 study showed around 20 million new cancer cases and nearly nine million deaths worldwide, with lung and breast cancer being the most common. Cancer cases are projected to rise to 35 million by 2050, according to the Union for International Cancer Control. The complexity of cancer requires tailored treatment approaches, leading to higher demand for clinical trials and research services provided by CROs.

2. Increasing Emphasis on Personalized Medicine

The increasing emphasis on personalized medicine is a major driver behind the growth of the oncology based in-vivo CRO market. Personalized medical care, medicines, and diagnostics were estimated to account for around 40% of total revenue in 2022, according to Statista, with oncology representing the most significant therapeutic area for personalized medicine. Tailoring treatments to individual patients improves efficacy, reduces adverse effects, and enhances overall treatment outcomes, driving demand for CROs with dedicated personalized medicine expertise.

3. Technological Advancements in Tumor Imaging and Monitoring

Increasing technological advancements are escalating demand for oncology based in-vivo CROs. Improved imaging modalities, such as PET-CT, MRI, and molecular imaging techniques, have enabled better visualization and monitoring of tumors in vivo. For instance, in June 2024, Siemens Healthineers launched the Biograph Trinion PET/CT scanner, featuring lutetium oxyorthosilicate (LSO) crystal detector elements delivering high spatial resolution and ultrafast time-of-flight performance of 239 picoseconds, enabling fast scans and low patient radiation doses.

4. Growing Adoption of Virtual and Decentralized Clinical Trials

The wide availability of personalized treatment techniques, along with the expanding healthcare industry, is catalyzing demand for oncology based in-vivo CRO services worldwide. There is also an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry to ensure the safety of cancer patients, which is projected to bolster market growth further.

5. Regulatory Compliance and Customized Trial Protocol Demand

Regulatory and compliance burdens, alongside the increasing demand for customized clinical trial protocols, continue to shape the competitive landscape of the oncology based in-vivo CRO industry. At the same time, AI-driven algorithms for data analytics, predictive modeling, and patient stratification are enhancing efficiency and decision-making in oncology research, presenting significant opportunities for market participants.

Key Market Segmentation

By Indication

Solid Tumors - Largest Segment: Solid tumors are the most common type of cancer, encompassing a wide range of malignancies such as breast, lung, colorectal, and prostate cancers. Their prevalence ensures a large patient population for clinical trials, making them attractive for CROs and pharmaceutical companies. The American Cancer Society estimated nearly 1,685,210 new cancer cases and 595,690 deaths in the United States in 2021 alone.

Blood Cancer: Blood cancer research relies heavily on in-vivo CRO services for evaluating novel hematologic oncology therapeutics, including targeted and immunotherapy-based treatment approaches.

Others: Includes rare and emerging cancer indications requiring specialized preclinical modeling and study design expertise.

By Model

Patient Derived Xenograft (PDX) - Largest Segment: PDX models involve implanting patient-derived tumor tissue into immunodeficient mice, preserving the molecular and histological characteristics of the original tumor. This model closely mimics human tumor biology and heterogeneity, making it invaluable for studying cancer progression, metastasis, and treatment response. Pharmaceutical and biotech firms rely on PDX studies to assess drug efficacy, optimize treatment regimens, and identify potential biomarkers for patient stratification.

Xenograft: Xenograft models remain a widely used approach for evaluating tumor growth inhibition and therapeutic response using established human cancer cell lines.

Syngeneic: Syngeneic models, using immunocompetent mice, are gaining traction for immuno-oncology research given their ability to model interactions between tumors and an intact immune system.

Others: Includes emerging and hybrid in-vivo modeling approaches supporting specialized oncology research needs.

By Application

Hospitals - Largest Segment: Hospitals frequently collaborate with CROs to conduct clinical trials for evaluating new oncology treatments. CROs provide expertise in study design, protocol development, patient recruitment, and regulatory compliance, enabling hospitals to participate in cutting-edge research without diverting resources from patient care.

Rehabilitation Centers: Rehabilitation centers may participate in clinical trials focused on cancer survivors who require rehabilitation services to improve quality of life post-treatment, with CROs supporting such trials through expertise in study design, outcome measures, and data management specific to this patient population.

Regional Oncology Based In-Vivo CRO Market Analysis

North America currently dominates the global market. The rising incidence of cancer cases in the region continues to drive demand for innovative therapies and treatment options. The Globocan 2021 report estimated that nearly 2,281,000 new cancer cases were diagnosed in the United States in 2021, with almost 612,000 fatalities. Oncology-focused CROs play a critical role in advancing research and development efforts to address unmet medical needs across various cancer types, supported by continuous advancements in molecular profiling, genomic sequencing, and imaging technologies.

Connect for Detailed Oncology Based In-Vivo CRO Market Share Segmentation Analysis - Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=5438&flag=C

Leading Players in the Global Oncology Based In-Vivo CRO Industry

The global oncology based in-vivo CRO market features a mix of specialized preclinical research providers and diversified contract research organizations. Key companies covered in the IMARC Group report include:

• Champions Oncology Inc.
• Charles River Laboratories International Inc.
• Crown Bioscience Inc.
• Eurofins Scientific
• Evotec SE
• ICON Plc
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• Living Tumor Laboratory
• Taconic Biosciences Inc.
• The Jackson Laboratory
• WuXi AppTec
• Xentech

Latest Oncology Based In-Vivo CRO Market Industry Developments

June 2024 - Siemens Healthineers

Siemens Healthineers launched the Biograph Trinion, its latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging, enhancing tumor visualization and monitoring capabilities relevant to oncology in-vivo research.

May 2024 - NHS, BioNTech and Genentech

The NHS launched a clinical trial in which patients received customized cancer vaccinations created by BioNTech and Genentech, using mRNA technology personalized to individual cancer mutations.

March 2024 - Veeda Clinical Research Limited

Veeda Clinical Research Limited, a contract research organization with a track record of successful drug development, acquired Heads, a privately held European CRO conducting oncology clinical trials.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104